EUVIMEDEUVIMED entdecken
Übersichtsarbeit

PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications

Miguel A Ortega iD, Diego Liviu Boaru, Diego De Leon-Oliva, Oscar Fraile-Martinez, Cielo García-Montero, Laura Rios, Maria J Garrido-Gil, Silvestra Barrena-Blázquez, Ana M Minaya-Bravo, Antonio Rios-Parra, Melchor Álvarez-Mon, Laura Jiménez-Álvarez und 4 weitere

Journal of Molecular Medicine · 2024-08 · 102 (8) · 987-1000

DOI: 10.1007/s00109-024-02463-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Molecular Medicine, online erschienen am 27.06.2024. Verfasst von Miguel A Ortega und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Medical Specialties, Faculty of Medicine and Health Sciences, CIBEREHD, University of Alcalá, 28801, Alcala de Henares, Sp…. Hauptthemen laut MEDLINE: Neoplasms, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Tumor Microenvironment. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 171 Literaturangaben. Gefördert von: Comunidad de Madrid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsB7-H1 AntigenProgrammed Cell Death 1 ReceptorTumor MicroenvironmentHumansAnimalsSignal TransductionDisease ProgressionImmunomodulationTranslational Research, Biomedical

Stichwörter der Autor:innen

CancerImmune checkpoint inhibitors (ICIs)PI3K/AKT pathwayPredictive biomarkersProgrammed cell death 1 ligand (PD-L1)Programmed cell death protein 1 (PD-1)

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorCD274 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Medicine and Medical Specialties, Faculty of Medicine and Health Sciences, CIBEREHD, University of Alcalá, 28801, Alcala de Henares, Spain. miguelangel.ortega@uah.es.
  • Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034, Madrid, Spain. miguelangel.ortega@uah.es.
  • Cancer Registry and Pathology Department, Principe de, Asturias University Hospital, Alcala de Henares, Spain. miguelangel.ortega@uah.es.
  • Department of Medicine and Medical Specialties, Faculty of Medicine and Health Sciences, CIBEREHD, University of Alcalá, 28801, Alcala de Henares, Spain.
  • Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034, Madrid, Spain.
  • Department of Nursing and Physiotherapy, Faculty of Medicine and Health Sciences, University of Alcalá, 28801, Alcala de Henares, Spain.

ORCID-Profile: Miguel A Ortega

Förderung

  • Comunidad de Madrid

Zitieren

APA

Ortega, M. A., Boaru, D. L., De Leon-Oliva, D., Fraile-Martinez, O., García-Montero, C., Rios, L., Garrido-Gil, M. J., Barrena-Blázquez, S., Minaya-Bravo, A. M., Rios-Parra, A., Álvarez-Mon, M., Jiménez-Álvarez, L., López-González, L., Guijarro, L. G., Diaz, R., & Saez, M. A. (2024). PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications. Journal of Molecular Medicine, 102(8), 987-1000. https://doi.org/10.1007/s00109-024-02463-3

Vancouver

Ortega MA, Boaru DL, De Leon-Oliva D, Fraile-Martinez O, García-Montero C, Rios L, et al. PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications. Journal of Molecular Medicine. 2024;102(8):987-1000. doi:10.1007/s00109-024-02463-3

BibTeX
@article{Ortega2024,
  author = {Ortega, Miguel A and Boaru, Diego Liviu and De Leon-Oliva, Diego and Fraile-Martinez, Oscar and García-Montero, Cielo and Rios, Laura and Garrido-Gil, Maria J and Barrena-Blázquez, Silvestra and Minaya-Bravo, Ana M and Rios-Parra, Antonio and Álvarez-Mon, Melchor and Jiménez-Álvarez, Laura and López-González, Laura and Guijarro, Luis G and Diaz, Raul and Saez, Miguel A},
  title = {PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications},
  journal = {Journal of Molecular Medicine},
  year = {2024},
  volume = {102},
  number = {8},
  pages = {987--1000},
  doi = {10.1007/s00109-024-02463-3}
}
Kostenlos starten →